The overall purpose of this study is to assess the safety and efficacy of human anti-CMV monoclonal antibody (MSL 109) with matched placebo, as supplemental treatment to ongoing primary treatment, for both newly diagnosed and relapsed CMV retinitis patients with AIDS.
Showing the most recent 10 out of 1085 publications